1 Alcaide F,Calatayud L,Santin M,et al. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drug9 against Mycobacterium kansasii [J]. Antimicrobm Agents Chemother,2004,48：4562-4565
2 Garcia-Tapia A, Rodriguez JC, Ruiz M, et al. Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis [J]. Chemotherapy，2004,50:211-213
3 Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis [J].Antimicrobm Agents Chemother, 2003,47 ： 653-657
4 Rodriguez JC y Cebrian L, Lopez M, et al. Mutant prevention concentra-tion ：comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis[J]. J Antimicrob Chemother,2004,53 ：441-444
5 Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxi-floxacin in patients with pulmonary tuberculosis [J]. Am J Respir Crit Care Med,2003,168：1342-1345
6 Pletz MW,De Roux A,Roth A, et al. Early bactericidal activity of moxi-floxacin in treatment of pulmonary tuberculosis：a prospective, randomized study [J]. Antimicrob Agents Chemother, 2004,48:780-782
7 Veziris N,Lounis N,ChaufTour A,et al. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice[J]. Antimicrob Agents Chemother,2005,49 ：4015-4019
8 Fattoririi L,Tan D，Iona E, et al. Activities of moxifloxacin alone and in combination with other antimicrobial agents multidrug-resistant Mycobac-terium tuberculosis infection in BALB/c mice [J]. Antimicrob AgentsChemother, 2003,47:360-362
9 Paramasivan CN,Sulochana S，Kubendiran G,et al. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phasecultures of Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother,2005,49:627-631
10 Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis [J]. Antimicrob Agents Chemother, 2002,46 ： 1022-1025
11 Alcala L,Ruiz-Serrano, MJ,Perez-Fernandez-Turegano C,et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tubercu-losis that are susceptible or resistant to first-line antituberculous drugs [J]. Antimicrob Agents Chemother,2003,47：416-417
12 Yang SC,Hsueh PR,Lai HC,et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan[J]. Antimicrob Agents Chemother, 2003,47：1958-1962
13 Erturan Z,Uzun M. In vitro activity of linezolid against multidrug-resis-tant Mycobacterium tuberculosis isolates [J]. Int J Antimicrob Agents,2005,26:78-80
14 Fortun J,Martin-Davila P,Navas E,et al. Linezolid for the treatment of multidrug- resistant tuberculosis [J]. J Antimicrob Chemother, 2005,56:180-185
15 Cabrera LV, Garza JC, Rendon A, et al. In vitro susceptibility of My-cobacterium tuberculosis clinical strains to garenoxacin and DA-7867[J]. Antimicrob Agents Chemother, 2005，49:4351-4353
16 Bae SK,Chung WS,Kim EJ,et al.Pharmacokinetics of DA-7867,a new oxazolidinone,after intravenous or oral administration to rats：intestinal first-pass effect [J]. Antimicrob Agents Chemother, 2004,48 ：659-662
17 Andries K, Verhasselt P, Guillemont J,et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis[J]. Science,2005,307:223-227
18 Stover CK, Warrener P, VanDevanter DR,et al. A small-molecule ni-troimidazopyran drug candidate for the treatment of tuberculosis [J]. Nature, 2000,405：962-966
19 Cresset J, Nuemberger E, Yoshimatsu T, et al. The nitroimidazopyran PA-824 has promising activity in the mouse model of TB [J]. Am J Respir Crit Care Med, 2004,169(Suppl) ：260
20 Tyagi S,Nuermberger E, Yoshimatsu T,et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis [J] . An-timicrob Agents Chemother,2005,49： 2289-2293
21 Lenaerts AJ, Gruppo V,Marietta KS,et al. Preclinical testing of the ni-troimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models [J]. Antimicrob Agents Chemother, 2005,49 ：2294-2301
22 Diedda D, Lampis G, Fioravinti R, et al. Bactericidal activities of the pyrrole derivative BM212 aginst multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains [J]. Antimicrob Agents Chemother,1998,42:3035-3037
23 Biava M. BM 212 and its derivatives as a new class of antimycobacterial active agefits[J]. Curr Med Chem,2002,9:1859-1869
24 Biava M, Porretta GC, Poce G, et al. Antimycobacterial compounds. Optimization of the BSf^.12 structure，the lead compound for a new pyrrolederivative class[J]. Bioorg Med Chem,2005,13:1221-1230
25 Lee R,Protopopova M，Crooks E, et al. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis pre-clinical candidates[J]. J Comb Chem,2003,5:172-187
26 Boshoff HI, Myers TG, Copp BR, et al. The transcriptional reponses of M. tuberculosis to inhibitors of metabolism ： novel insights into drug mechanisms of action[J]. J Biol Chem,2004,279:40174-40184
27 Jia L,Tomaszewski JE，Hanrahan C,et al. Pharmacodynamics and phar-macokinetics of SQ109, a new diamine-based antitubercular drug[J]. BrPharmacol, 2005,144:80-87
|
京公网安备11010202007215号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
